Decreased strain and rotation were hypothesized to be associated with the presence and extent of left ventricular myocardial fibrosis in Duchenne muscular dystrophy. Investigators recently ...

—An analysis of population-based data revealed that males born with DMD experienced prolonged survival when cardiac medication was initiated while LVF was normal, highlighting an area of focus for ...

Newport Beach-based nonprofit Coalition Duchenne has awarded a $150,000 grant to a Cedars-Sinai Heart Institute team investigating whether an experimental cardiac stem cell treatment could be used to ...

Reduced progression of myocardial fibrosis measured by LGE on cardiac MRI (p=0.022)Significant improvement in LVEF versus placebo in patients with baseline cardiomyopathy (p=0.017)Global Statistical ...

Capricor Therapeutics Inc. (NASDAQ:CAPR) is one of the best hot stocks to buy according to analysts. On March 12, Capricor Therapeutics presented new late-breaking data from its Phase 3 HOPE-3 ...

Solid Biosciences’ SGT-003 is the only late‑stage program to show early cardiac benefit across biomarkers and function, according to William Blair.

Detailed price information for Tenaya Therapeutics Inc (TNYA-Q) from The Globe and Mail including charting and trades.

This week saw both Regenxbio and Solid Bio report new data with their gene therapy candidates for Duchenne muscular dystrophy ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202, a potential best-in-class gene therapy for Duchenne muscular dystrophy.

Duchenne type muscular dystrophy (DMD) is the most common hereditary muscular disease among children, leaving them wheelchair-bound before the age of 12 and reducing life expectancy. Researchers have ...